loadpatents
Patent applications and USPTO patent grants for GERRITSEN; Arnout F..The latest application filed is for "production of heterodimeric proteins".
Patent | Date |
---|---|
Production Of Heterodimeric Proteins App 20200048304 - GRAMER; Michael ;   et al. | 2020-02-13 |
Bispecific And Multispecific Antibodies And Method For Isolation Of Such App 20180201693 - HIBBERT; Richard G. ;   et al. | 2018-07-19 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) Grant 9,458,236 - Van De Winkel , et al. October 4, 2 | 2016-10-04 |
Human Monoclonal Antibodies To Epidermal Growth Factor Receptor (egfr) App 20140141006 - VAN DE WINKEL; Jan G. J. ;   et al. | 2014-05-22 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) Grant 8,586,041 - van de Winkel , et al. November 19, 2 | 2013-11-19 |
Human monoclonal antibodies against CD20 Grant 7,850,962 - Teeling , et al. December 14, 2 | 2010-12-14 |
High Throughput Methods For Characterization Of Antibodies App 20100041874 - Gerritsen; Arnout F. ;   et al. | 2010-02-18 |
Human Monoclonal Antibodies To Epidermal Growth Factor Receptor (egfr) App 20100008929 - van de Winkel; Jan G. J. ;   et al. | 2010-01-14 |
Method for treating psoriasis by administering human antibodies specific for Interleukin 15 (IL-15) Grant 7,597,892 - Van de Winkel , et al. October 6, 2 | 2009-10-06 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) Grant 7,595,378 - van de Winkel , et al. September 29, 2 | 2009-09-29 |
Nucleic acid encoding human antibodies specific for interleukin 15 (IL-15) Grant 7,585,961 - Van De Winkel , et al. September 8, 2 | 2009-09-08 |
Human Monoclonal Antibodies Against Cd20 App 20080260641 - Teeling; Jessica ;   et al. | 2008-10-23 |
Human antibodies specific for interleukin 15 (IL-15) App 20080166347 - van de Winkel; Jan G.J. ;   et al. | 2008-07-10 |
Human antibodies specific for interleukin 15 (IL-15) App 20080166802 - van de Winkel; Jan G.J. ;   et al. | 2008-07-10 |
Human antibodies specific for interleukin 15 (IL-15) Grant 7,329,405 - van de Winkel , et al. February 12, 2 | 2008-02-12 |
Human monoclonal antibodies to FC gamma receptor II (CD32) App 20070253958 - Van De Winkel; Jan G. J. ;   et al. | 2007-11-01 |
Methods of treating using anti-IL-15 antibodies Grant 7,247,304 - van de Winkel , et al. July 24, 2 | 2007-07-24 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) Grant 7,247,301 - van de Winkel , et al. July 24, 2 | 2007-07-24 |
Human antibodies specific for interleukin 15 (IL-15) Grant 7,153,507 - van de Winkel , et al. December 26, 2 | 2006-12-26 |
Human antibodies specific for interleukin 15 (IL-15) App 20040071702 - van de Winkel, Jan G.J. ;   et al. | 2004-04-15 |
Human antibodies specific for interleukin 15 (IL-15) App 20030235586 - van de Winkel, Jan G.J. ;   et al. | 2003-12-25 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) App 20030194403 - van de Winkel, Jan G.J. ;   et al. | 2003-10-16 |
Human Antibodies specific for interleukin 15 (IL-15) App 20030138421 - van de Winkel, Jan G.J. ;   et al. | 2003-07-24 |
Human monoclonal antibodies to epidermal growth factor receptor (EGFR) App 20030091561 - van de Winkel, Jan G.J. ;   et al. | 2003-05-15 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.